Particularly, the ability of the phytochemicals of the nutraceutical GliceFen® (Mivell, Fano, Italy) to reduce Semaphorin 3E protein levels, increase insulin receptor (INSR) levels, and inhibit DPPIV catalytic activity identifies this nutraceutical as a natural adjuvant for innovative T2DM therapeutic approaches in combination with synthetic drugs [4]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.